| Objective This study mainly starts with the treatment of burning mouth syndrome(BMS)with traditional Chinese and western medicine,and focuses on the study of traditional Chinese medicine in terms of psycho psychological medication,providing further theoretical basis for the development of new treatment methods for BMS,aiming to study the efficacy of Shugan Jieyu Capsule in the treatment of burning mouth syndrome and its impact on the pain,anxiety,depression and safety of BMS patients.Methods From December 2021 to April 2022,60 patients with BMS were diagnosed in the Department of Oral Mucosa of the Fourth Affiliated Hospital of Inner Mongolia Medical University,including 16 males and 44 females;The age range is from 18 to 55.The patients were randomly divided into experimental group(30 cases)and control group(30 cases).The age,sex and course of disease were matched,with no statistical significance.The control group was given Guweisu tablets+vitamin B2+vitamin E capsules,and the experimental group was given Shugan Jieyu capsules on the basis of the control group.Physician A records the general situation of BMS patients,and uses self-rating anxiety scale(SAS)and Self Rating Depression Scale(SDS)to evaluate the anxiety and depression of the subjects,and uses visual analog scale(VAS)to evaluate the degree of pain,adverse reactions and clinical efficacy of the subjects.SPSS software was used for statistical analysis of the data,the difference was statistically significant(P<0.05).Results 1.There were 7 males and 23 females in the experimental group;The average age was(34.65 ± 4.57)years;The average course of disease was(9.42 ± 3.35)months.The control group consisted of 9 males and 21 females,with a mean age of(33.80 ± 5.21)years;The average course of disease was(9.27 ± 3.26)months,which are no obvious difference in the general data between the two groups(P>0.05),which was balanced and comparable.2.During the treatment of the two groups of BMS patients,the SAS score of the experimental group was(55.25 ± 6.34)points before treatment and(46.33 ± 5.25)points after treatment.The SAS score after treatment was obviously lower than that before treatment(P<0.05).The SAS score of the control group was(54.65 ± 6.87)before treatment and(49.75 ± 5.54)after treatment.The SAS score after treatment was obviously lower than that before treatment(P<0.05).Before treatment,the SAS scores of the experimental group and the control group were not statistically significant(P>0.05).After treatment,the SAS score of the experimental group was obviously lower than that of the control group(P<0.05).3.During the treatment of the two groups of BMS patients,the SDS score of the experimental group was(65.22 ± 5.44)before treatment and(47.84 ± 5.38)after treatment.The SDS score after treatment was obviously lower than that before treatment,with statistical significance(P<0.05).The SDS score of the control group was(64.15 ± 6.21)points before treatment and(50.36 ± 5.27)points after treatment.The SDS score after treatment was obviously lower than that before treatment(P<0.05).Before treatment,the SDS scores of the experimental group and the control group were not statistically significant(P>0.05).After treatment,the SDS score of the experimental group was significantly lower than that of the control group(P<0.05).4.During the treatment of the two groups of BMS patients,the VAS score of the experimental group was(5.27 ± 1.36)before treatment and(3.35 ± 0.91)after treatment.The VAS score after treatment was obviously lower than that before treatment,with statistical significance(P<0.05).The VAS score of the control group was(5.11 ± 1.43)before treatment and(3.96 ±1.12)after treatment.The VAS score after treatment was obviously lower than that before treatment(P<0.05).Before treatment,the VAS scores of the experimental group and the control group were not statistically significant(P>0.05).After treatment,the VAS score of the experimental group was obviously lower than that of the control group(P<0.05).5.During the treatment of the two groups of BMS patients,the experimental group had 22 cases of significant effectiveness,7 cases of effectiveness,1 case of ineffectiveness,and the total effective rate was 96.67%,while the control group had 13 cases of significant effectiveness,11 cases of effectiveness,and 6 cases of ineffectiveness,and the total effective rate was80.00%.The total effective rate of the experimental group was obviously higher than that of the control group(P<0.05).6.During the treatment of the two groups of BMS patients,the experimental group had 3 cases of adverse reactions,and 2 cases of adverse reactions in the control group,which was no significant difference(10.00% vs 6.67%)in the rate of adverse reactions between the two groups(P>0.05).Conclusions Based on the treatment of conventional western medicine,Shugan Jieyu Capsule is given to BMS patients to relieve their pain,relieve anxiety and depression,improve clinical efficacy,have high safety,and open up a new method for clinical treatment of BMS. |
PDF Full Text Request